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ORIGINAL ARTICLE
Silk nanoparticles: proof of lysosomotropic anticancer drug delivery at single-cell
resolution
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ABSTRACT
Silk nanoparticles are expected to improve chemotherapeutic drug targeting to solid tumours by exploit-
ing tumour pathophysiology, modifying the cellular pharmacokinetics of the payload and ultimately
resulting in trafficking to lysosomes and triggering drug release. However, experimental proof for lysoso-
motropic drug delivery by silk nanoparticles in live cells is lacking and the importance of lysosomal pH
and enzymes controlling drug release is currently unknown. Here, we demonstrate, in live single human
breast cancer cells, the role of the lysosomal environment in determining silk nanoparticle-mediated drug
release. MCF-7 human breast cancer cells endocytosed and trafficked drug-loaded native and PEGylated
silk nanoparticles (100nm in diameter) to lysosomes, with subsequent drug release from the respective
carriers and nuclear translocation within 5 h of dosing. A combination of low pH and enzymatic degrad-
ation facilitated drug release from the silk nanoparticles; perturbation of the acidic lysosomal pH and inhib-
ition of serine, cysteine and threonine proteases resulted in a 42%±2.2% and 33%±3% reduction in
nuclear-associated drug accumulation for native and PEGylated silk nanoparticles, respectively. Overall, this
study demonstrates the importance of lysosomal activity for anticancer drug release from silk nanopar-
ticles, thereby providing direct evidence for lysosomotropic drug delivery in live cells.
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Introduction
Nanomedicine was defined in the early 2000s by the European
Science Foundation as ‘the use of nanosized tools for the diagnosis,
prevention and treatment of disease’ [1]. While the terminology is
new, research into the use of therapeutic nanomaterials has been
underway since the early 1970s. This has resulted in the clinical
approval of over 40 nanomedicines that are now used as nanoimag-
ing and analytical tools, drugs and drug delivery systems [2]. Today,
nanomedicines are used routinely in the clinic for the treatment of
type 2 diabetes (e.g. Welchol), electrolyte imbalance (e.g. Renagel,
Veltassa), multiple sclerosis (e.g. Copaxone), and solid tumours and
leukaemias (e.g. Doxil, Abraxane, Oncaspar), as well as for lymphatic
mapping in patients with solid tumours (e.g. Lymphoseek) [3].
The design of anticancer nanomedicines for solid tumour tar-
geting typically exploits the enhanced permeability and retention
(EPR) effect, where the leaky vasculature and poor lymphatic
drainage at the tumour site promotes (passive) nanomedicine
accumulation [4,5]. Often, the nanomedicines are designed for
intracellular activation (e.g. exposure to enzymes, low pH, etc.)
that triggers drug release. Therefore, endocytic uptake and correct
intracellular routing (i.e. third order targeting [6,7]) is critical for
achieving the desired pharmacological effect. This type of target-
ing has the potential to overcome drug resistance mechanisms
(e.g. plasma membrane drug efflux pumps) by changing the
mechanism of cellular entry of small molecular weight payload(s)
from a physicochemically driven partitioning process to an energy-
dependent endocytic uptake mechanism. The subsequent
accumulation of nanomedicines in lysosomes, the triggered pay-
load release from the carrier and the ensuing movement of the
liberated drug from the lysosomes to its pharmacological site of
action inside the cell is a process known as lysosomotropic drug
delivery [8], a term first proposed and demonstrated by de Duve
[6,9].
The approval of nanoparticles for drug delivery to solid tumours,
such as albumin-based paclitaxel nanoparticles (e.g. Abraxane, ABI-
009) in 2005, has catalysed the field to develop second-generation
nanoparticles for this purpose [10]. Biopolymer-based constructs
(e.g. cyclodextrin CRLX-101) [11], mannose and diethylenetriamine-
pentaacetic acid 99mTc-functionlised dextran [12] and proteins
[13,14] are especially appealing because their inherent biodegrad-
ability renders them less likely to disrupt lysosomal function [3].
One important protein in this respect is silk, which has recently
been proposed for use in drug delivery applications [15,16]. Silk has
been used for centuries as a suture material, confirming its bio-
logical safety, and it can be fully reverse-engineered to create novel
material formats, including silk nanoparticles (reviewed by Seib
[15]). Silk, as a natural biopolymer, has remarkable capabilities to
stabilise and protect therapeutic payloads (e.g. proteins, peptides
and drugs) [17]. The silk protein is biocompatible and biodegrad-
able [18] and silk fibres and surgical meshes are approved for use in
humans [15]. Most processes begin with Bombyx mori silk, reverse
engineer the cocoon, and use an aqueous silk solution to manufac-
ture (nano)particles [15]. The overall particle characteristics can be
fine-tuned though the selection of processing conditions, for
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example capillary microdot printing [19], salting out [20], polyvinyl
alcohol blending [21], electrospraying [22], electric field application
[23], supercritical fluid technologies [24], ionic liquid utilisation [25]
and organic solvent desolvation [26–28]. Of these processing strat-
egies, desolvation is a robust and reproducible method for produc-
ing silk nanoparticles of uniform size (100 nm, Figure 1(B)) and
with long-term stability [15,29,30]. The 100 nm size range is well
suited for exploitation of the steps required for lysosomotropic
drug delivery, including the EPR effect [4] for solid tumour accumu-
lation, subsequent endocytic uptake [31] and trafficking through
the endocytic machinery of the cell to the lysosomes [7]. Silk nano-
particles can also be surface-decorated with polyethylene glycol
(PEG) to reduce particle–protein interactions [32], thereby reducing
clearance by the reticular endothelial system and improving (pas-
sive) tumour targeting.
To date, attempts to characterise lysosomotropic drug release
from silk nanoparticles have been conducted by measuring drug
release from silk nanoparticles in buffer solutions that mimic the
pH of the lysosome (pH 4.5–5.5) (reviewed by Seib [15]). While
these studies provide a useful indication of the role of pH on drug
release, they fail to consider the influence of lysosomal enzymatic
activity on drug release, as well as the barrier to drug release
created by the lysosomal vesicle. Overall, drug release studies in
solution cannot faithfully recapitulate the lysosomal microenviron-
ment; thus, they represent a gross oversimplification of lysosomo-
tropic payload delivery. Our aim was therefore to address these
limitations and to assess the roles of lysosomal pH and enzymatic
degradation, both individually and in combination, on (i) drug
release from silk and PEGylated silk nanoparticles, and (ii) lysoso-
motropic drug delivery, by studying doxorubicin delivery to
human breast cancer cells at single-cell resolution.
Methods
Preparation of native and PEGylated silk nanoparticles
Bombyx mori silk cocoons were reverse-engineered and the result-
ing aqueous silk solution was subjected to desolvation to generate
silk nanoparticles, as described previously [28,29]; for a visual
protocol format, see the work by Wongpinyochit et al. [30]. These
native silk nanoparticles were surface-decorated with PEG [29] by
reacting 50mg of silk nanoparticles with 50mg methoxypolyethy-
lene glycol activated with cyanuric chloride (TST-activated mPEG,
5000 g/mol, Sigma-Aldrich, St. Louis, MO) overnight in 2ml of
50mM Na2B4O7, pH 9.4, with constant stirring at 4
C. The sample
was then washed with ultrapure water and analysed as detailed
previously [29].
Characterisation of native and PEGylated silk nanoparticles
The size distribution and zeta potential of native and PEGylated
silk nanoparticles in water were measured by dynamic light scat-
tering (DLS) using a Zetasizer Nano-ZS (Malvern Instrument,
Worcestershire, UK). Refractive indices of 1.33 for water and 1.60
for protein were used to compute the particle size. The particles
were visualised by scanning electron microscopy (SEM) as follows:
native and PEGylated silk nanoparticles were diluted with ultra-
pure water to a concentration of 1mg/mL. The samples were then
pipetted onto a silicon wafer and lyophilised overnight. The speci-
mens were sputter-coated with carbon using a vacuum coater
(Polaron Division E6100, Bio-Rad, Birmingham, UK) and viewed
with a FE-SEM SU6600 (Hitachi High Technologies, Krefeld,
Germany) at 5 kV and a 40,000-fold magnification.
Doxorubicin-loaded native and PEGylated silk nanoparticles
A 0.2 mmol/ml doxorubicin solution was prepared by dissolving
116 mg doxorubicin HCl (LC Laboratories, Boston, MA) in 1ml of
ultrapure water. Next, 200ml of 10mg of native or PEGylated silk
nanoparticles was mixed with 2ml of 232 mg doxorubicin. After a
24-h incubation at room temperature, the samples were centri-
fuged for 30min at 194,000g using a fixed-angel rotor
(Beckman Coulter 50.2 Ti, Brea, CA). Doxorubicin-associated fluor-
escence (excitation/emission 480 nm/590 nm, POLARstar Omega,
BMG Labtech GmbH, Germany) in the supernatant was used to
determine the residual drug concentration remaining in solution
with the aid of a doxorubicin calibration curve.
Drug release of doxorubicin-loaded native and PEGylated silk
nanoparticles under acidic conditions in the presence and
absence of papain
Doxorubicin-loaded nanoparticles (native or PEGylated) and
unloaded control nanoparticles were washed twice with ultrapure
water and resuspended in 0.5ml of PBS at pH 5 in the absence or
presence of 1mg/ml of papain (Sigma-Aldrich, St. Louis, MO, 10
units/mg protein), a lysosomal-like enzyme. The samples were
loaded into a 0.1ml Slide-A-Lyzer Mini Dialysis Device (MWCO
3500 g mol1; Thermo Scientific, Waltham, MA), which was then
inserted into a 1.5ml receiver chamber containing 1.05ml of buf-
fer at the indicated conditions, followed by incubation at 37 C. At
the indicated time points, doxorubicin-associated fluorescence in
the receive chamber was monitored. Fresh buffer was added at
each time point to ensure that sink conditions were maintained
throughout the study. A calibration curve of doxorubicin in PBS at
pH 5 was used to quantify drug release. The percentage of cumu-
lative drug release was determined as a function of the incubation
time.
Labelling native and PEGylated silk nanoparticles with Alexa
Fluor
VR
488
Nanoparticles labelled with Alexa Fluor
VR
488 (AF488) were used to
trace their intracellular fate in MCF-7 cells. Fluorescent labelling
was based on the method detailed previously [29]. Briefly, a total
of 5mg of native or PEGylated silk nanoparticles were fluores-
cently labelled with AF488. First, the nanoparticles were resus-
pended in 0.1M NaHCO3, pH 8.3. Next, 100 lL of 1mg/mL Alexa
Fluor
VR
488 succinimidyl ester (Life Technologies, Carlsbad, CA) was
dissolved in anhydrous dimethyl sulphoxide (DMSO), added to the
nanoparticles and allowed to react overnight at room temperature
in the dark with stirring. The labelled nanoparticles were then cen-
trifuged and washed four times with acidified water (pH 4.6) to
remove unbound dye, followed by three washes with ultrapure
water, and the samples were stored at 4 C in the dark until use.
The mean fluorescence intensity (MFI) of AF488-conjugated native
and PEGylated silk nanoparticles was measured with a microplate
reader to produce a standard curve (Supplementary Figure 1),
which was used to normalise nanoparticle-associated fluorescence
during the cell studies.
Cell culture
The human breast cancer cell line MCF-7 was purchased from
ATCC (Manassas, VA). Cells were cultured in DMEM (4.5 g glucose,
110mg sodium pyruvate, 10%v/v FBS and 10lg/mL insulin) in a
humidified 5% CO2 atmosphere at 37
C. Routine subculture was
2 J. D. TOTTEN ET AL.
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conducted every 2–3 days (when the cells had reached 80% con-
fluence) by trypsinisation and replating the cells at a ratio of
1:4–1:3. For all cell-based studies, MCF-7 cells were seeded at a
density of 2 104 cells/cm2 and allowed to recover for 24 h.
Uptake and trafficking of native and PEGylated silk
nanoparticles by MCF-7 cells
For flow cytometry and microscopy, the cells were seeded and cul-
tured using complete culture medium but without phenol red.
The cells were washed three times with PBS and the culture
medium was replaced with either (i) control DMEM or (ii) DMEM
supplemented with 0.5mg/ml native or PEGylated silk nanopar-
ticles. The cells were incubated for 5 h in the absence and pres-
ence of 50 nM LysoTracker
VR
Red (Thermo Scientific, Waltham, MA).
The incubation was stopped by placing cells on ice, aspirating all
the medium and washing three times with ice-cold PBS to remove
unbound nanoparticles from the wells. Live cells were then (i)
trypsinised and harvested into 5-ml Falcon tubes for analysis by
flow cytometry, or (ii) stained with 1lg/ml Hoechst 33342
(Thermo Scientific, Waltham, MA) for 10min, washed three times
with ice-cold PBS and imaged immediately by live confocal micros-
copy (detailed below).
Flow cytometry
Flow cytometry data acquisition was conducted on a BD
FACSCanto instrument (Becton Dickinson, San Jose, CA) using BD
FACSDiva software v6.3.1 (Becton Dickinson, San Jose, CA). A min-
imum of >9000 events were recorded within a gate that was veri-
fied to contain live singlets (Supplementary Figure 2), and the
geometric mean fluorescence intensity was measured using the
instrument’s FITC filter (530/30 nm). Subsequent data analysis was
conducted using FlowJo v10.1 (Tree Star, San Carlos, CA). When
analysing the AF488-conjugated native and PEGylated silk nano-
particles, the differences in the raw fluorescence of the particles
were normalised using the fluorescent standard described above
(Supplementary Figure 1).
Localisation of doxorubicin in the nucleus of live MCF-7 cells
Cells were washed three times with PBS and the medium was
replaced with either (i) control DMEM or (ii) DMEM supplemented
with 10mM leupeptin (Sigma-Aldrich, St. Louis, MO), 10mM
ammonium chloride (NH4Cl) (Sigma-Aldrich, St. Louis, MO) or a
combination of both. Cells were returned to the incubator for 1 h
to allow the inhibitors to take effect [33]. The media were then
aspirated and replaced with the same respective inhibitors,
together with either (i) 0.3lg/ml doxorubicin or (ii) 0.5mg/ml
native or PEGylated silk nanoparticles loaded with an equivalent
drug concentration. Cells were incubated at 37 C for 5 h to allow
sufficient time for nuclear delivery of doxorubicin by each formula-
tion. The incubation was stopped by placing the cells on ice and
preparing them for analysis by confocal microscopy as detailed
above. The inhibitory effects of NH4Cl were verified by modifying
the above setup to use LysoTracker
VR
Red. This enabled staining of
Figure 1. Manufacture and characterisation of native and PEGylated silk nanoparticles. (A) Processes for generating native and PEGylated silk nanoparticles and scan-
ning electron microscopy images of each nanoparticle population. (B) Particle size and zeta potential measurement of native and PEGylated silk nanoparticles using
dynamic light scattering (DLS) (n¼ 3).
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acidic vesicles after 5 h in the absence and presence of NH4Cl
(Supplementary Figure 3).
Confocal microscopy
Confocal imaging was conducted on live cells immediately after
dosing using a Leica TCS-SP5 confocal laser scanning microscope
(Leica Microsystems GmbH, Wetzlar, Germany) equipped with a
40magnification water objective with a numerical aperture of
1.25. Single confocal sections were acquired at an airy disc of 1.
Subsequent image analysis was conducted using ImageJ v1.51k 1
(National Institutes of Health, Bethesda, MD) [34]. The localisation
of AF488-conjugated native and PEGylated silk nanoparticles to
lysosomes was determined by drawing a 15 lm line through indi-
vidual cells in multicolour images and plotting the signal intensity
of AF488 and LysoTracker
VR
Red along the line. Areas of colocalisa-
tion were then identified as peaks on a profile plot. The lysosomo-
tropic drug delivery was assessed by splitting the Hoechst and
doxorubicin channels of each image, identifying individual nuclei
(Supplementary Figure 4(A), centre) and then applying the regions
of interest (ROIs) to the doxorubicin channel (Supplementary Figure
4(A), right). A minimum of six background ROIs were identified and
the mean fluorescence of background readings, along with selected
nuclear areas and integrated densities, was used to determine the
nuclear-associated fluorescence (Supplementary Figure 4(A,B).
Statistical analyses
Data were plotted and analysed using GraphPad Prism 7.0a
(GraphPad Software, La Jolla, CA). Sample pairs were analysed
with the Student’s t-test. Multiple samples were evaluated by a
two-way analysis of variance (ANOVA) followed by Bonferroni’s mul-
tiple comparison post hoc test. Asterisks denote statistical signifi-
cance, as follows: p< .05, p< .01, p< .001. Unless otherwise
stated, data are presented as mean values ± standard deviation (SD)
and refer to the number of biological independent experiments.
Results
Characterisation of native and PEGylated silk nanoparticles
Silk nanoparticles were generated using nanoprecipitation by add-
ing the reverse-engineered silk solution dropwise to acetone
(Figure 1(A)). This method yielded a uniform particle size
(98.49 ± 3.7 nm with narrow polydispersity 0.095), and negative
surface charges (42.60 ± 0.72mV) (Figure 1(B)) (n¼ 3). Qualitative
measurement using SEM verified the size and spherical shape of
these nanoparticles (Figure 1(A)). TsT-activated mPEG was used to
decorate the surface of silk nanoparticles, using previously
described methods [29]. Successful surface modification was deter-
mined by calculating the amount of surface-grafted PEG and then
measuring the particle size and zeta potential. The amount of sur-
face-grafted PEG for 50mg silk nanoparticles was 10.72 ± 0.82mg
PEG. PEGylation increased the apparent particle size from 98.49 to
105.30 nm and reduced the surface charge from42.60
to36.77mV (Figure 1(B)). The nanoparticles were then labelled
with AF488 or loaded with doxorubicin.
Cellular binding, uptake and trafficking of native and PEGylated
silk nanoparticles
Flow cytometry analyses showed that MCF-7 cells dosed with
native silk nanoparticles displayed a significantly higher cell-
Figure 2. Native and PEGylated silk nanoparticle uptake and lysosomal trafficking. (A) Assessment of cell-associated fluorescence by flow cytometry and (B) live-cell
confocal imaging of MCF-7 cells treated for 5 h with AF488-conjugated native (SNPs) or PEGylated silk nanoparticles (PEG-SNPs). Boxes (top right) on the images repre-
sent the normalised cell-associated fluorescence values. (C) Live-cell confocal images of cells dosed for 5 h with LysoTracker
VR
Red, together with either AF488-conju-
gated SNPs or PEG-SNPs. Arrowheads identify the location of the 15lm line used in profile plots to highlight the lysosomal regions of colocalisation. Representative
images of single confocal slices, scale bars ¼10lm; n¼ 3, ± SD.
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associated fluorescence when compared to cells treated with
PEGylated silk nanoparticles (Figure 2(A)). These differences were
also observed using live-cell confocal microscopy, and the native
silk nanoparticles were observed to aggregate more readily than
the PEGylated silk nanoparticles (Figure 2(B)). Analysis of each con-
focal image revealed similar differences in the normalised cell-
associated fluorescence between the native and PEGylated silk
nanoparticles that agreed with the flow cytometry results (Figure
2(B), numbers shown on the image). The cells were also dosed in
the presence of the lysosomal marker LysoTracker
VR
Red, which
confirmed that both native and PEGylated silk nanoparticles were
internalised and trafficked to the lysosomes (Figure 2(C)).
In vitro drug loading and drug release of doxorubicin-loaded
native and PEGylated silk nanoparticles under acidic conditions
in the presence and absence of papain
The native and PEGylated silk nanoparticles, supplied at 10mg, had
encapsulation efficiencies of 98.3%± 0.13 and 97.91%±0.08,
respectively, when exposed to 232 mg doxorubicin (Figure 3(A))
(n¼ 3). The respective zeta potentials of the doxorubicin-loaded
native and PEGylated silk nanoparticles were significantly reduced,
by 10% and 20%, respectively, when compared to unloaded con-
trols (Figure 3(B)) (n¼ 3). Doxorubicin release by native and
PEGylated silk nanoparticles was measured in PBS at pH 5 in the
absence and presence of papain, a cysteine protease enzyme which
mimics the enzymatic activity of lysosomal enzymes [35,36]. In the
absence of papain, pH alone was sufficient to liberate doxorubicin
from both native and PEGylated silk nanoparticles, but the
PEGylated silk nanoparticles displayed a 4-fold greater doxorubicin
release when compared to their native counterparts (Figure 3 (C,D))
(n¼ 3). The addition of papain consistently enhanced the doxorubi-
cin release from the native and PEGylated silk nanoparticles (Figure
3(C)). Significant doxorubicin release from PEGylated silk nanopar-
ticles occurred at 4 h and the release remained high at 6 h (Figure
3(D)). Overall, PEGylated silk nanoparticles showed a> 4-fold higher
cumulative drug release in the presence of papain when compared
to release from the papain-treated native silk nanoparticles.
Native and PEGylated silk nanoparticles facilitate
lysosomotropic anticancer drug delivery
The model system using PBS pH 5 and papain suggested that
both pH and enzymes are important for drug release from silk
nanoparticles (Figure 3(C,D)). Therefore, the role of lysosomal acid-
ification and proteolytic lysosomal enzymes for silk-mediated lyso-
somotropic drug delivery was further assessed in human breast
cancer cells at single-cell resolution. This was achieved by monitor-
ing the doxorubicin-associated nuclear fluorescence following dos-
ing with doxorubicin-loaded native or PEGylated silk nanoparticles
for 5 h or with freely diffusible doxorubicin at the equivalent dose
(serving as the control). We used established inhibitors of lyso-
somal acidification (NH4Cl) [33,37] and enzymatic activity (leupep-
tin) [33], singly and in combination, to assess their impact on
doxorubicin-associated nuclear fluorescence (Figure 4(A)).
Doxorubicin delivery by native silk nanoparticles displayed a
significant reliance on both lysosomal enzyme activity and pH, as
total nuclear-associated fluorescence decreased by 17% and 36%,
in the presence of the respective inhibitors (Figure 4(B), left). Drug
delivery by PEGylated silk nanoparticles was significantly reduced
by inhibitor treatment; lysosomal enzymatic activity and acidifica-
tion resulted in 12% and 20% reductions in nuclear-associated
doxorubicin fluorescence, respectively (Figure 4(B), centre).
Combination treatments with leupeptin and NH4Cl reduced the
nuclear-associated fluorescence by 42% and 33% for native and
PEGylated silk nanoparticles, respectively.
The same cell model was then used to determine the differen-
ces in nuclear localisation of freely diffusible doxorubicin (Figure
4(B), right). Inhibition of lysosomal enzymatic activity had no sig-
nificant effect on doxorubicin-associated nuclear fluorescence.
Figure 3. Characterisation and drug release from native and PEGylated silk nanoparticles. (A) Doxorubicin encapsulation efficiency for 10mg of native and PEGylated
silk nanoparticles. (B) Zeta potential (mV) of doxorubicin-loaded silk nanoparticles compared to unloaded controls. Cumulative doxorubicin release from (C) native and
(D) PEGylated silk nanoparticles in PBS at pH 5 in the presence and absence of 1mg/ml papain. Data are the means of three independent experiments ± SD; error bars
are hidden in the plot–symbol when not visible.
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However, acidification reduced the nuclear-associated doxorubicin
fluorescence by 11%. The combined inhibition of both pH and
enzymatic activity resulted in a 22% reduction in nuclear-associ-
ated fluorescence (Figure 4(B), right panel).
Discussion
Silk is increasing in popularity as a biomaterial for drug delivery,
as confirmed by the current availability of several silk-based for-
mulations, including tablets [38], hydrogels [39,40], scaffolds [41],
films [42] and particles [15,26,27,30]. These advancements are sup-
ported by the decades of extensive clinical experience with the
use of silk in humans in load-bearing applications (e.g. sutures and
surgical meshes) [43,44]. Its hierarchical structure endows silk with
unique mechanical properties in its native fibre format; these proper-
ties arise predominantly from the block copolymer arrangement of
crystalline and amorphous segments within the silk heavy chain [15].
In addition, liquid silk, as stored in the silk gland or reverse engi-
neered, adopts a micellar conformation in solution, which current silk
nanoparticle manufacturing protocols now exploit, typically by
inducing b-sheets within the crystalline domains to generate physic-
ally cross-linked nanoparticles with exquisite stability [15].
The silk nanocrystalline regions provide a number of unique
advantages for drug delivery: they exert a buffering action, tailor
water content at the nanoscale, provide physical protection and
reduce payload mobility (thereby improving the stability of pep-
tide and protein drugs) [17]. Native silk nanoparticles can also be
modified in several ways, for example by surface decoration with
PEG, which improves stability in biological buffer systems and elimi-
nates cytokine release from macrophages [29], or by inclusion of
ultra-small Fe3O4 nanoparticles during silk nanoparticle manufacture
to yield magnetic field responsive silk nanoparticles with enhanced
in vivo solid tumour targeting [45] via the EPR effect.
Emerging evidence now supports the use of silk nanoparticles
(100 nm in size) for anticancer drug delivery by third order tar-
geting [15]. For example, we have documented a pH-dependent
drug release from silk nanoparticles (with model buffers of differ-
ent pH) [28]. We have also provided evidence that silk nanopar-
ticles are internalised and trafficked to the lysosomes of human
breast cancer cells [28]. However, this means that drug release
studies from silk nanoparticles must also consider the influence of
carrier degradation by lysosomal enzymes on drug release. For
this reason, we set out to examine the effects of lysosomal
enzyme activity on drug release, using a combination of in vitro
and cell-based models.
We used a well-characterised nanoprecipitation method to gen-
erate native and PEGylated silk nanoparticles of a similar uniform size
and charge (Figure 1(B)) to those used in previous studies [28–30].
The native and PEGylated silk nanoparticles were both readily endo-
cytosed by MCF-7 cells over the 5 h incubation period, with no appar-
ent differences in lysosomal trafficking (Figure 2(C)). Doxorubicin was
our choice of model drug for loading both native and PEGylated silk
nanoparticles because (i) it is a clinically relevant anticancer drug,
(ii) its site of action is the nucleus, making it ideally suited for monitor-
ing lysosomotropic drug delivery, (iii) its intracellular distribution is
Figure 4. Lysosomal enzyme degradation and acidification play a significant role in facilitating nuclear delivery of doxorubicin by native and PEGylated silk nanopar-
ticles. (A) Representative live confocal microscopy images showing the role of lysosomal enzymes and acidification on doxorubicin delivery mediated by native (SNPs)
and PEGylated (PEG-SNPs) silk nanoparticles; freely diffusible doxorubicin at the equivalent dose served as a control. Note doxorubicin is inherently autofluorescent.
Images are single confocal slices, boxed area and respective higher magnification image; scale bars ¼10lm. (B) Nuclear-associated fluorescence of MCF-7 cells treated
for 5 h with freely diffusible doxorubicin or doxorubicin-loaded native or PEGylated silk nanoparticles in the absence (n¼ 106–132) or presence of (i) leupeptin
(n¼ 95–152), (ii) NH4Cl (n¼ 103–144) or (iii) a combination treatment (n¼ 115–156). Data from two independent experiments (n¼ 2)± standard error of the mean.
6 J. D. TOTTEN ET AL.
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ity
 of
 St
rat
hc
lyd
e] 
at 
01
:57
 23
 A
ug
us
t 2
01
7 
well documented and (iv) its intracellular distribution in single live
cells is readily tracked by fluorescence microscopy.
Drug loading and the subsequent changes in zeta potential of
native and PEGylated silk nanoparticles (Figure 3) correlated well
with previously published work (e.g. [30]). Furthermore, doxorubi-
cin released from silk nanoparticles showed the expected pH-
dependent profile (pH 4.5 6.5> 7.4); these selected pH values
mimic the pH environment of lysosomes, endosomes and the
blood plasma, respectively. We further mimicked the lysosomal-
like environment by including papain, a cysteine protease enzyme.
The structure and enzymatic properties of papain have high simi-
larity to mammalian lysosomal enzymes (e.g. cathepsins B, H, L, S)
[35]. Doxorubicin was liberated more rapidly from the PEGylated
silk nanoparticles than from native silk nanoparticles at low pH, in
both the presence and absence of papain.
Differences in doxorubicin release from native and PEGylated
silk nanoparticle are expected, because PEGylation changes the
acidic surface properties of silk nanoparticles (for a detailed discus-
sion, see the work by Wongpinyochit et al. [29]). The inclusion of
papain did not significantly affect the liberation of doxorubicin
from PEGylated silk nanoparticles in the first 2 h (Figure 3(D)),
whereas the native silk nanoparticles showed already significant
increases in doxorubicin release in the first 2 h in the presence of
papain (Figure 3(C)). This suggests that PEGylation confers some
protection against lysosomal enzyme degradation of the silk nano-
particles, with the end result being a delay in the time taken to
trigger doxorubicin release. Overall, the ability of papain to
increase doxorubicin release from protein nanoparticles is
expected. For example, previous work using silica nanoparticles
coated with sericin (derived from B. mori cocoons) showed that
the presence of papain increased doxorubicin release 2-fold [46].
We next examined the lysosomotropic delivery of doxorubicin
into human breast cancer cells using native and PEGylated silk
nanoparticles. Localisation of doxorubicin to the nucleus was
selected as the marker for successful drug delivery. Leupeptin and
ammonium chloride were selected as well-established inhibitors to
assess the role of lysosomal enzymatic activity and acidification,
respectively [33]. For the lysosomotropic delivery of doxorubicin to
the nucleus, these inhibitors, both individually and in combination,
are widely used for in vitro assessment of nanomedicine perform-
ance (e.g. [46]). In the present study, treatment with leupeptin and
ammonium chloride resulted in notable decreases in the nuclear-
associated fluorescence of MCF-7 cells when compared to control
cells dosed in the absence of the inhibitors (Figure 4(A)). Analysis
of nuclear-associated fluorescence of single cells showed a slightly
higher dependence on enzymatic degradation for the native silk
nanoparticles than for the PEGylated silk nanoparticles (Figure
4(B)), in agreement with the results from our papain study (Figure
3 (C,D)). For both the native and PEGylated silk nanoparticles, a
larger role was indicated for lysosomal acidification alone than for
lysosomal enzymatic activity alone in facilitating the nuclear localisa-
tion of doxorubicin. One plausible explanation is that drug release
due to enzymatic degradation is comparatively slower [33] than pH-
dependent drug release due to the time required for enzymatic deg-
radation of the solid silk nanoparticle to liberate the drug.
The greatest changes in lysosomotropic drug delivery for either
the native or the PEGylated silk nanoparticles were seen following
simultaneous manipulation of both the pH and the proteolytic lyso-
somal environment (Figure 4(B)). This suggests that doxorubicin
release from silk nanoparticles in live cells is mediated by both pH
and proteolytic enzymes. However, the relative importance of each is
difficult to unravel because the low pH in lysosomes contributes to
‘acid trapping’ of the weakly basic doxorubicin within the lysosomes
[47], while an increase in intracellular pH modifies the
transmembrane and intracellular partitioning of doxorubicin [48].
Furthermore, optimal lysosomal enzyme activity is also pH depend-
ent [49].
Conclusions
Native and PEGylated silk nanoparticles loaded with doxorubicin
were trafficked to lysosomes of living cells. Once there, a combin-
ation of lysosomal pH and enzymatic degradation facilitated doxo-
rubicin release and the relocalisation of the drug to the nucleus.
These results demonstrate the importance of both pH and lyso-
somal enzyme activity on drug release from silk nanoparticles and
provide the first experimental proof of lysosomotropic drug deliv-
ery in live cells.
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